These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 27318333

  • 41. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ.
    Clin Infect Dis; 2008 Jul 01; 47(1):56-62. PubMed ID: 18491964
    [Abstract] [Full Text] [Related]

  • 42. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
    Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL.
    Clin Infect Dis; 2019 May 30; 68(12):2003-2009. PubMed ID: 30256954
    [Abstract] [Full Text] [Related]

  • 43. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence.
    Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT.
    Am J Gastroenterol; 2019 Dec 30; 114(12):1904-1908. PubMed ID: 31714359
    [Abstract] [Full Text] [Related]

  • 44. Does Prophylaxis Prevent Recurrent Clostridioides difficile Infection?
    Berger RE.
    NEJM Evid; 2022 Apr 30; 1(4):EVIDtt2200026. PubMed ID: 38319213
    [Abstract] [Full Text] [Related]

  • 45. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection.
    Chang LL, Allegretti J, Skinner AM, Dubberke ER.
    N Engl J Med; 2023 Feb 16; 388(7):654-656. PubMed ID: 36791167
    [No Abstract] [Full Text] [Related]

  • 46. Firvanq--vancomycin oral solution.
    Med Lett Drugs Ther; 2018 Jul 16; 60(1551):122. PubMed ID: 30036349
    [No Abstract] [Full Text] [Related]

  • 47. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
    Brown CC, Manis MM, Bohm NM, Curry SR.
    Ann Pharmacother; 2019 Apr 16; 53(4):396-401. PubMed ID: 30450942
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Intracolonic administration of vancomycin for Clostridium difficile infection.
    Grimm M, Rafael T.
    Nursing; 2014 Sep 16; 44(9):58-60. PubMed ID: 25140945
    [No Abstract] [Full Text] [Related]

  • 51. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
    El-Herte RI, Baban TA, Kanj SS.
    Scand J Infect Dis; 2012 Mar 16; 44(3):228-30. PubMed ID: 22077098
    [Abstract] [Full Text] [Related]

  • 52. [Approach to the treatment of intestinal infectious diseases caused by Clostridium difficile].
    Nyc O.
    Klin Mikrobiol Infekc Lek; 2010 Jun 16; 16(3):93-6. PubMed ID: 20640987
    [Abstract] [Full Text] [Related]

  • 53. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile.
    Early CR, Park JM, Dorsch MP, Pogue KT, Hanigan SM.
    Transpl Infect Dis; 2016 Oct 16; 18(5):714-720. PubMed ID: 27501504
    [Abstract] [Full Text] [Related]

  • 54. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH, CoDIFy study group.
    Lancet Infect Dis; 2017 Jul 16; 17(7):735-744. PubMed ID: 28461207
    [Abstract] [Full Text] [Related]

  • 55. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
    Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D.
    CMAJ; 2004 Aug 31; 171(5):466-72. PubMed ID: 15337727
    [Abstract] [Full Text] [Related]

  • 56. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection.
    Russo A, Falcone M, Fantoni M, Murri R, Masucci L, Carfagna P, Ghezzi MC, Posteraro B, Sanguinetti M, Venditti M.
    Clin Microbiol Infect; 2015 May 31; 21(5):493.e1-4. PubMed ID: 25698658
    [Abstract] [Full Text] [Related]

  • 57. Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.
    Sun Y, Huskey RL, Tang L, Inaba H, Gaur AH, Ribeiro R, Rubnitz JE, Wolf J.
    Antimicrob Agents Chemother; 2018 Mar 31; 62(3):. PubMed ID: 29229640
    [Abstract] [Full Text] [Related]

  • 58. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
    Morrow T.
    Manag Care; 2011 Jul 31; 20(7):49-50. PubMed ID: 21848202
    [No Abstract] [Full Text] [Related]

  • 59. Vancomycin "telephone".
    Drekonja DM.
    Clin Infect Dis; 2011 Jul 15; 53(2):211-2. PubMed ID: 21690636
    [No Abstract] [Full Text] [Related]

  • 60. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS.
    Surg Infect (Larchmt); 2011 Jun 15; 12(3):235-9. PubMed ID: 21767157
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.